Regeneron stock stands at EUR 678.75 with P/ E of 18.8

Published on 10/12/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock costs EUR 678.75 on October 12, 2026. Its USD 78.3 billion market cap sits within a USD 541.00 to USD 859.34 range.

Key points in brief

Regeneron stock was trading at EUR 678.75 at Lang & Schwarz on October 12, 2026 at 4:01 p.m. CEST.
The Nasdaq quote was USD 759.87 at 10:05 a.m. EDT, with market capitalization of USD 78.3 billion.
The primary-market 52-week range was USD 541.00 to USD 859.34, while the P/E ratio was 18.79.
Regeneron is scheduled to report third-quarter 2026 results on October 30, 2026.

Schwarzweiß-Dokumentarfoto einer Wissenschaftlerin bei der Laborarbeit mit Pipette — Regeneron Pharma US75886F1075 illustriert eine dokumentarische Schwarzweiß-Reportage einer Wissenschaftlerin bei konzentrierter Antikörper-Laborarbeit im Forschungsraum, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) was trading at EUR 678.75 at Lang & Schwarz on October 12, 2026 at 4:01 p.m. CEST. The quote carried a bid of EUR 677.00 and an ask of EUR 680.50, giving German investors a live euro view of the biotechnology company.

Euro quote stays separate

The home-market quote was USD 759.87 at 10:05 a.m. EDT on October 12, 2026, according to the latest Nasdaq-linked market reading. The USD figure is shown separately from the Lang & Schwarz quote because the two prices use different currencies and venues.

Regeneron's market capitalization was USD 78.3 billion at that U.S. market reading. Its trailing P/E ratio was 18.79, while the trailing dividend yield was 0.00 percent.

Range leaves a wide frame

The primary-market 52-week range was USD 541.00 to USD 859.34 as of October 12, 2026. The current USD quote therefore stood below the yearly high and above the yearly low, placing the stock within a broad trading frame rather than at an extreme.

For German investors, the practical distinction is important: the EUR 678.75 quote is the local trading reference, while the USD 759.87 Nasdaq quote supplies the separated home-market context. No currency conversion is used to combine the two values.

Results date is October 30

Regeneron announced on September 24, 2026 that it will report third-quarter 2026 financial and operating results on October 30, 2026, before the U.S. financial markets open. The company also scheduled its conference call for 8:30 a.m. EDT that day.

Comparison with peers

Regeneron (Nasdaq, USD): P/E 18.8, market capitalization USD 78.3 billion

Eli Lilly (NYSE, USD): plus 0.27 percent, P/E 39.8, market capitalization USD 1,113.6 billion

Vertex Pharmaceuticals (Nasdaq, USD): plus 0.37 percent, P/E 29.8, market capitalization USD 129.9 billion

Market view for Regeneron

Regeneron's valuation multiple was lower than those of Eli Lilly and Vertex Pharmaceuticals in the October 12, 2026 market readings, while its market capitalization was also smaller than both peer values. The October 30 reporting date is the next scheduled company-specific calendar point.

Regeneron quote remains current

The latest Lang & Schwarz reading was EUR 678.75 on October 12, 2026 at 4:01 p.m. CEST, with bid and ask quotes of EUR 677.00 and EUR 680.50. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.